Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Combination treatment

This page shows the latest Combination treatment news and features for those working in and with pharma, biotech and healthcare.

AbbVie’s Parkinson’s disease therapy application rejected by FDA

AbbVie’s Parkinson’s disease therapy application rejected by FDA

ABBV-95 is a combination of foscarbidopa and foslevodopa, the prodrugs for the commonly used carbidopa and levodopa (CD/LD). ... a new treatment that can enable better symptom control through the continuous 24-hour administration of medication".

Latest news

More from news
Approximately 0 fully matching, plus 355 partially matching documents found.

Latest Intelligence

  • As COVID-19 takes over the world, biopharma fights back As COVID-19 takes over the world, biopharma fights back

    A combination HIV treatment: AbbVie’s Kaletra. In an unprecedented move, AbbVie has suspended its patents on its combination HIV drug Kaletra, after it was identified as having potential against ... The combination drug was first included in Chinese

  • Deal Watch April 2016 Deal Watch April 2016

    Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... 85 . Dong A (SK). Tobira (US). Cross license. Evogliptin

  • Pharma deals in April 2015 Pharma deals in April 2015

    No deal terms were disclosed. The initial development plan will look at the combination therapy as a potential treatment for NHL. ... The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid.

  • Pharma deals during July 2014 Pharma deals during July 2014

    The acquisition of Almirall's respiratory business enhances AZ's respiratory franchise bringing a portfolio of marketed and developmental single and combination products for the treatment of asthma and COPD. ... tremelimumab. Existing partners

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    And again, matching drugs that work well together will be crucial going forward: “Combination treatment will be a critical component; how best to put these drugs together with other checkpoint inhibitors, ... This includes people with NSCLC who have a

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • What does the future hold for Light-chain Amyloidosis?

    approval in combination with CyBorD for the treatment of newly diagnosed adult patients with AL amyloidosis. ... Prior to the approval of a new combination treatment for use across Europe, we conducted the first wave of our research to generate a

  • Oncosec

    body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; ... Results from recently completed

  • Marketing strategy in complex environments

    The last few years have seen influential scientific advances, resulting in subtle shifts in how pharma tackles disease treatment. ... The treatment of aggressive diseases often benefits very noticeably from combination therapy, especially when involving

More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...

Quick links